1. Japan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
COSMOS Pharmaceutical Corporation

COSMOS Pharmaceutical Corporation

6,324.00
JPY
+1.00
(+0.02%)
700.00BMarket Cap
Jan 08Next Earn
COSMOS Pharmaceutical Corporation
TSE:3349
(Tokyo Stock Exchange)

Recent

price

6,324.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
2,994.63
3,523.02
4,158.03
4,694.82
5,157.49
5,647.5
6,347.76
7,045.6
7,716.55
8,641.64
9,172.23
9,538.29
10,451.02
12,178.18
12,761.05
13,873.59
- -
Revenue per Share
72.44
97.69
118.64
133.84
147.65
157.01
229.99
222.64
242.24
270.65
342.89
292.37
300.48
308.61
390.86
404.33
- -
Basic EPS, GAAP
94.52
62.59
9.28
73.46
-131.45
-1.34
104.43
39.58
67.41
498.91
22.87
-142.72
98.46
-8.01
-10.84
-147.27
- -
Free Cash Flow per Basic Share
5.74
13.25
10.49
13.74
14.37
15.62
17.49
22.49
22.49
26.23
28.75
41.24
41.24
58.8
62.57
74.97
- -
Dividend per Share
374.89
459.35
567.56
686.87
821.42
961.88
1,174.94
1,374.88
1,594.59
1,839.37
2,153.81
2,405.46
2,665.12
2,920.12
3,248.45
3,579.48
3,248.45
Book Value per Share
366.81
449.44
557.43
678.3
815.24
957.68
1,172.22
1,371.15
1,590.97
1,835.99
2,149.7
2,399.99
2,658.22
2,913.85
3,242.82
3,567.71
3,242.82
Tangible Book Value per Share
79
79
79
79
79
79
79
79
79
79
79
79
79
79
79
79
79
Basic Weighted Avg Shares
237,174
279,021
329,313
371,825
408,466
447,273
502,732
557,999
611,137
684,403
726,424
755,414
827,697
964,989
1,011,390
1,099,583
- -
Sales/Revenue/Turnover
4.23
4.78
4.72
4.49
4.18
4.17
4.42
4.08
4.05
4.25
4.56
3.94
3.64
3.26
3.99
3.85
- -
Operating Margin (%)
2,362
3,104
4,247
5,604
7,342
9,588
10,710
11,885
12,958
13,562
13,785
15,110
17,368
19,924
22,229
24,576
- -
Depreciation Expense
5,737
7,737
9,396
10,600
11,694
12,435
18,215
17,633
19,185
21,435
27,156
23,155
23,797
24,454
30,978
32,046
- -
Net Income, GAAP
45.71
46.26
43.57
42.44
39.78
39.33
29.23
29.94
29.31
29.49
29.64
29.93
27.39
27.48
26.89
27.52
- -
Effective Tax Rate (%)
2.42
2.77
2.85
2.85
2.86
2.78
3.62
3.16
3.14
3.13
3.74
3.07
2.88
2.53
3.06
2.91
- -
Profit Margin (%)
-6,618
-11,328
-19,016
-24,265
-31,202
-32,552
-40,383
-49,111
-52,785
-47,800
-34,412
-46,592
-54,968
-58,896
-55,058
-55,982
-55,058
Working Capital
4,360
2,803
1,951
4,390
11,734
20,099
15,504
12,172
10,698
9,029
7,349
6,357
13,716
27,551
42,019
67,180
42,019
LT Debt
29,691
36,380
44,950
54,399
65,055
76,179
93,053
108,888
126,289
145,675
170,578
190,507
211,072
231,442
257,463
283,700
257,463
Total Equity
13.28
16.6
17.7
16.19
13.45
11.58
13.75
12.66
12.61
13.11
13.04
10.54
9.93
8.98
9.98
8.88
- -
Return on Invested Capital (%)
16.32
19.84
20.9
19.39
16.38
13.5
16.8
14.69
14.45
14.42
16.05
12.18
11.11
9.91
10.88
9.7
- -
Return on Capital (%)
21.21
23.42
23.11
21.34
19.58
17.61
21.53
17.46
16.32
15.76
17.17
12.83
11.85
11.05
12.67
11.84
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Aug'25
Nov'25
May'25
ST Debt
- -
4,331
7,938
LT Borrowings
- -
21,344
37,202
LT Finance Leases
- -
- -
4,817
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
79
79
79
Market Capitalization
565,898
585,315
700,000

Working Capital

JPY

•

in mil. unless spec.
Aug'25
Nov'25
May'25
Total Current Assets
- -
150,020
165,622
Cash, Cash Equivalents & STI
- -
39,129
57,038
Accounts Receivable, Net
- -
683
761
Inventories
- -
93,850
92,323
Total Current Liabilities
- -
212,833
220,680
Payables & Accruals
- -
- -
- -
ST Debt
- -
4,331
7,938
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.11%
10.71%
10.19%
Free Cash Flow
-705.72%
58.56%
1,258.79%
Net Income, GAAP
11.14%
4.19%
3.45%
Sales/Revenue/Turnover
9.47%
8.74%
8.72%
Total Cash Common Dividend
- -
- -
19.82%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
241,653
234,777
238,881
249,678
964,989
2025
- -
- -
- -
- -
1,011,390
2026
- -
- -
- -
- -
1,099,583

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
82.18
64.1
72.8
89.54
308.61
2025
- -
- -
- -
- -
390.86
2026
- -
- -
- -
- -
404.33

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
58.8
2025
- -
- -
- -
- -
62.57
2026
- -
- -
- -
- -
74.97
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
COSMOS Pharmaceutical Corporation operates primarily as a leading drugstore chain in Japan, founded in 1973 and headquartered in Fukuoka. The company markets a comprehensive range of products including general medicines, energy drinks, oral and nursing care products, vitamins, health foods, dietary and diet foods, prescriptions, cosmetics, skin and hair care products, makeup kits, detergents, insecticides, toiletries, kitchenware, garden supplies, clothing, car-related products, processed food, seasonings, bread, pastries, dairy products, beverages, liquor, tobacco, and cigarettes. COSMOS continues to expand its nationwide retail footprint supported by AI-driven supply chain optimization solutions to enhance product availability and operational efficiency. Recent major developments include securing CE certification for its advanced AI-powered colonoscopy platform, ColonPRO EU, reflecting its innovation in AI-powered healthcare; obtaining European Commission marketing authorization for Winlevi (clascoterone 10 mg/g cream), a novel dermatology product launched in partnership with Glenmark Pharmaceuticals, which also recently achieved regulatory approval in South Korea and Brazil. The company is executing a Vision 2030 strategy focused on growth across AI MedTech, dermatology, gastrointestinal innovation, and contract development and manufacturing (CDMO) services, reinforced by strong revenue performance and increased research and development investments in inflammatory bowel diseases. COSMOS leverages a diverse product portfolio, advanced technology, and strategic alliances to maintain its leadership in the pharmaceutical retail industry and specialty healthcare market in Japan and selected international markets.